Clade-specific influences of glycans on the interactions between HIV-1 envelope and broadly neutralizing antibodies
Mrinal ArandharaiD, Yogendra KumariD, Narendra M. DixitiD, Prabal Kumar MaitiiD
Abstract
N-linked glycans are important in the elicitation and the activity of many broadly neutralizing antibodies (bNAbs) against HIV-1. The high conformational flexibility of glycans hindered detailed atomistic investigations of glycan-bNAb interactions, including glycan shielding of bN-Abs. Importantly, how these interactions vary across different HIV-1 clades remains unclear. The variability in the number and location of potential N-linked glycosylation sites (PNGS) on the HIV-1 envelope (Env) protein across clades can lead to differences in glycan dynamics and topology, potentially affecting Env-bNAb interactions and the clade-specific efficacy of bNAb-based therapies. Here, we combined comprehensive glycan conformational sampling, using the software glycoSHIELD, and molecular dynamics (MD) simulations to model fully glycosylated trimeric Env for six HIV-1 strains, one from each of the major clades A, B, C, G, CRF01 AE (01 AE) and CRF07 BC (07 BC). We assessed the interactions of 50 different bNAbs, drawn from all the major bNAb classes, with each of these strains, quantifying glycan shielding, glycan-bNAb interactions, and their clade-specific variations for each bNAb in microscopic detail. Our findings reveal that while glycans cover most of the exposed surface area in all clades, the amount of accessible surface varies, with clade B having the minimum and clade 07 BC the maximum antibody accessible surface area. The number of glycan conformers per glycosylation site also varies with clades, even for conserved sites. Overall, we observed that bNAbs interact with more glycans than previously reported in experimental and computational studies. Important variations emerge in Env-bNAb interactions with clade and bNAb-class. These atomic-level insights will be valuable for improving bNAb-based therapies and vaccine design strategies against HIV-1. TOC Graphic O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=111 SRC="FIGDIR/small/655089v2_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@eedc04org.highwire.dtl.DTLVardef@1aebf67org.highwire.dtl.DTLVardef@1982a02org.highwire.dtl.DTLVardef@ee08e5_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 0.50
- Field percentile
- top 36%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Extensive global HIV-1 sequence diversity perturbs conserved features of the envelope glycan shield
Maddy L. Newby, Joel D. Allen, … Max Crispin·bioRxiv·Aug 21, 2026
- Impact of glycan positioning on HIV-1 Env glycan shield density, function, and antibody recognition
Q. Wei, A. A. Harget, … J. Novak·bioRxiv·Mar 31, 2020
- Identification of a broad and potent V3 glycan site bNAb targeting anN332gp120 glycan-independent epitope
Lutz Gieselmann, Andrew T. DeLaitsch, … Florian Klein·bioRxiv·Sep 5, 2025
- Broadly Neutralizing Antibody Epitopes on HIV-1 Particles are exposed after Virus Interaction with Host Cells
P. G. Rao, G. S. Lambert, C. Upadhyay·bioRxiv·Jan 20, 2023
- Characterization of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformational States on Infectious Virus Particles
H. T. Nguyen, Q. Wang, … J. G. Sodroski·bioRxiv·Dec 1, 2022
- Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted / founder sensitivity to broadly neutralizing antibodies
D. Parthasarathy, K. R. Pothula, … A. Herschhorn·bioRxiv·Sep 13, 2023